
China CDE Approves Global Phase III Study of Olverembatinib for SDH-Deficient GIST 2k714
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center […]